Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2024

This “Alpha 1 adrenergic receptor antagonist - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Alpha 1 adrenergic receptor antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Alpha 1 adrenergic receptor antagonist Understanding

Alpha 1 adrenergic receptor antagonist: Overview

Alpha-1-adrenergic receptors (ARs) are G protein-coupled receptors activated by catecholamines. The alpha-1A and alpha-1B subtypes are expressed in mouse and human myocardium, whereas the alpha-1D protein is found only in coronary arteries. The alpha-1 adrenergic receptors activate the Gq/11 family of G proteins leading to the dissociation of the a and ß? subunits and the subsequent stimulation of the enzyme phospholipase C. This enzyme hydrolyzes phosphatidylinositol 1,2-biphosphate in the membrane producing inositol trisphosphate (IP3) and diacylglycerol. These molecules act as second messengers mediating intracellular Ca2+ release via the IP3 receptor and activating protein kinase C. Alpha-1-adrenoreceptor antagonist drugs have the immediate attraction that there are no patient co-morbidities that constitute absolute contraindications to their use. Thus, alpha blockers can safely and appropriately be administered to hypertensive patients with concomitant disease states such as diabetes mellitus or obstructive airway disease or renal impairment.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Alpha 1 adrenergic receptor antagonist R&D. The therapies under development are focused on novel approaches for Alpha 1 adrenergic receptor antagonist.

Alpha 1 adrenergic receptor antagonist Emerging Drugs Chapters

This segment of the Alpha 1 adrenergic receptor antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alpha 1 adrenergic receptor antagonist Emerging Drugs

TNX-102 SL: Tonix Pharmaceuticals TNX-102 SL is a small, rapidly-disintegrating, under the tongue (sublingual) product candidate containing 2.8 mg of cyclobenzaprine HCl. The unique formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. Tonix is developing TNX-102 SL* as a potential treatment for the symptoms of Fibromyalgia. It is currently in Phase 3 clinical development. TNX-102 SL targets mechanisms which are associated with disturbed sleep. It is believed that increasing sleep quality in fibromyalgia may facilitate the body's adaptive ability to modulate the perception of pain.

Roluperidone: Minerva Neurosciences Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. When 5-HT2A is blocked, certain symptoms of schizophrenia, such as hallucinations, delusions, agitation and thought and movement disorders, as well as the side effects associated with antipsychotic treatments, can be minimized. Roluperidone has also been designed to block a specific subtype of sigma receptor called sigma2, which is involved in movement control, psychotic symptom control and learning and memory. Blocking sigma2, along with blocking the a-adrenergic subtypes a1A, and to a lesser extent a1B, also increases calcium levels in neurons in the brain, which can improve memory. Pre-clinical findings provide evidence of the effect of roluperidone on Brain-Derived Neurotrophic Factor (“BDNF”), which has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning andmemory.

Alpha 1 adrenergic receptor antagonist: Therapeutic Assessment

This segment of the report provides insights about the different Alpha 1 adrenergic receptor antagonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Alpha 1 adrenergic receptor antagonist

There are approx. 12+ key companies which are developing the Alpha 1 adrenergic receptor antagonist. The companies which have their Alpha 1 adrenergic receptor antagonist drug candidates in the most advanced stage, i.e. Phase III include, Tonix Pharmaceuticals.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Alpha 1 adrenergic receptor antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alpha 1 adrenergic receptor antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Alpha 1 adrenergic receptor antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha 1 adrenergic receptor antagonist drugs.

Alpha 1 adrenergic receptor antagonist Report Insights

• Alpha 1 adrenergic receptor antagonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Alpha 1 adrenergic receptor antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Alpha 1 adrenergic receptor antagonist drugs?
• How many Alpha 1 adrenergic receptor antagonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha 1 adrenergic receptor antagonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Alpha 1 adrenergic receptor antagonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alpha 1 adrenergic receptor antagonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tonix Pharmaceuticals
• Minerva Neurosciences
• INNOPHARMAX
• Bristol-Myers Squibb
• Kissei Pharmaceutical
• Pharmazz
• Ocularis Pharma
• Kinnov Therapeutics
• Ache Laboratories
• Ildong Pharmaceutical
• GL PharmTech
• Jeil Pharmaceutical
• Chong Kun Dang
• Ocuphire Pharma
• Fabre-Kramer Pharmaceuticals

Key Products

• TNX-102 SL
• Roluperidone (MIN-101)
• C 08001
• Aripiprazole
• FKF 02SC
• Silodosin
• Centhaquine
• Phentolamine
• KT 110
• Phentolamine/pilocarpine
• ACH 000029
• Tadalafil/tamsulosin
• GL2701 CKD-825
• JLP-1207

This product will be delivered within 2-4 business days.